Aerie Pharmaceuticals reported $6.93M in Cost of Sales for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Aerie Pharmaceuticals AERI:US USD 6.93M 3.19M
Alimera Sciences ALIM:US USD 2.01M 160K
Amarin AMRN:US USD 23.94M 11.87M
Cara Therapeutics CARA:US USD 3.06M 3.06M
Coherus Biosciences CHRS:US USD 35.23M 23.96M
Endo International Ordinary Shares ENDP:US USD 176.86M 1.06M
Horizon Pharma HZNP:US USD 234.13M 3.92M
Insmed INSM:US USD 13.47M 2.92M
Merk MRK:US USD 3.43B 715M
Novartis NOVN:VX USD 3.66B 92M
Pacira Pharmaceuticals PCRX:US USD 50.68M 51K
Regeneron Pharmaceuticals REGN:US USD 317.8M 20.7M
Revance Therapeutics RVNC:US USD 10.74M 1.21M
Supernus Pharmaceuticals SUPN:US USD 25.88M 5.42M
Teva Pharmaceutical Industries TEVA:US USD 1.88B 73M
Valeant Pharmaceuticals VRX:CN USD 584M 7M
Zoetis ZTS:US USD 606M 14M